
|Articles|February 24, 2015
- NSCLC (Issue 6)
- Volume 6
- Issue 1
Maintenance Therapies for Patients with Non-Small Cell Lung Cancer
Author(s)Benjamin P. Levy, MD
Benjamin P. Levy, MD, director of thoracic medical oncology, Mount Sinai Health System, discusses maintenance therapies for patients with non-small cell lung cancer.
Advertisement
Benjamin P. Levy, MD, assistant professor of medicine, Icahn School of Medicine at Mount Sinai, director of thoracic medical oncology, Mount Sinai Health System, discusses maintenance therapies for patients with non-small cell lung cancer.
<<<
Articles in this issue
over 11 years ago
Nanovesicles as Targeted Therapy for Lung Cancerover 11 years ago
Prior Cancer Diagnosis Not Viable Exclusion From Lung Cancer Trialsover 11 years ago
Liquid Biopsy Use in NSCLC Clinical Practice on the Horizonover 11 years ago
Lung Cancer Screening: Implementing the New Protocolover 11 years ago
Challenges Oncologists Face in Treating Lung Cancerover 11 years ago
Diagnostic Platforms for Lung Cancerover 11 years ago
Potential Modulator of NSCLC Metastasis IdentifiedAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Switching From Chemoimmunotherapy When a ROS1 Result Returns
2
Building an Adequate ROS1 Workup With RNA-Based Sequencing
3
Etentamig Improves Response, Survival in Phase 3 Trial for Relapsed/Refractory Myeloma
4
Ivonescimab Bests Pembrolizumab on Overall Survival in PD-L1+ NSCLC
5

































